Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Arcus Biosciences (RCUS) Income towards Parent Company: 2017-2024

Historic Income towards Parent Company for Arcus Biosciences (RCUS) over the last 8 years, with Dec 2024 value amounting to -$283.0 million.

  • Arcus Biosciences' Income towards Parent Company fell 46.74% to -$135.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$433.0 million, marking a year-over-year decrease of 60.37%. This contributed to the annual value of -$283.0 million for FY2024, which is 7.82% up from last year.
  • Per Arcus Biosciences' latest filing, its Income towards Parent Company stood at -$283.0 million for FY2024, which was up 7.82% from -$307.0 million recorded in FY2023.
  • Arcus Biosciences' 5-year Income towards Parent Company high stood at $53.0 million for FY2021, and its period low was -$307.0 million during FY2023.
  • Moreover, its 3-year median value for Income towards Parent Company was -$283.0 million (2024), whereas its average is -$285.7 million.
  • As far as peak fluctuations go, Arcus Biosciences' Income towards Parent Company skyrocketed by 143.09% in 2021, and later tumbled by 603.77% in 2022.
  • Over the past 5 years, Arcus Biosciences' Income towards Parent Company (Yearly) stood at -$123.0 million in 2020, then surged by 143.09% to $53.0 million in 2021, then tumbled by 603.77% to -$267.0 million in 2022, then fell by 14.98% to -$307.0 million in 2023, then increased by 7.82% to -$283.0 million in 2024.